Ballard P L, Gluckman P D, Liggins G C, Kaplan S L, Grumbach M M
Pediatr Res. 1980 Feb;14(2):122-7. doi: 10.1203/00006450-198002000-00011.
Prenatal maternal therapy with glucocorticoid reduces the incidence of respiratory distress syndrome (RDS) in premature infants. To investigate the effects of this treatment on the fetal endocrine system, we determined serum concentrations of betamethasone, cortisol, dehydroepiandrosterone sulfate, growth hormone, and prolactin in cord blood of 215 treated infants and 117 untreated infants of 26--36 wk of gestation. Cortisol levels are suppressed within 6 hr of betamethasone treatment, decrease to 45% of the concentration in untreated infants (8.4 micrograms/dl), and return to normal by 7 days. Dehydroepiandrosterone sulfate is reduced maximally by 65% and returns to normal concentrations (123.5 micrograms/dl in 7 1/2 days. The suppression of both steroids was similar after treatment with 12 mg betamethasone (acetate and phosphate) daily 2 times or with 6 mg betamethasone (alcohol) twice daily 4 times. Peak betamethasone levels were higher after the 12 mg dose, but the two-treatment regimens produced a similar total exposure of the fetus to elevated serum glucocorticoid activity for 2 1/2 days and decreased plasma activity for the subsequent 4 1/2 days. Treated infants with low cortisol concentrations at birth increased their cortisol levels severalfold after birth in response to either intrapartum asphyxia or RDS. Betamethasone therapy did not affect cord serum prolactin levels, but the concentration of growth hormone was reduced at all ages. The suppression was greatest (53% decrease) among infants of 28 less than 32 wk, and, among older infants, there was a subsequent increase above control levels between 2 and 4 days after treatment. This study indicates that prenatal betamethasone treatment causes a transient suppression of fetal growth hormone and presumably those pituitary hormones which regulate steroid production by both the definitive and fetal zones of the fetal adrenal. However, the suppression of fetal cortisol does not interfere with the pituitary-adrenocortical response to stress after birth.
产前给予母体糖皮质激素治疗可降低早产儿呼吸窘迫综合征(RDS)的发生率。为研究该治疗对胎儿内分泌系统的影响,我们测定了215例接受治疗的婴儿和117例未接受治疗的妊娠26 - 36周婴儿脐带血中倍他米松、皮质醇、硫酸脱氢表雄酮、生长激素和催乳素的血清浓度。倍他米松治疗后6小时内皮质醇水平受到抑制,降至未治疗婴儿浓度的45%(8.4微克/分升),并在7天内恢复正常。硫酸脱氢表雄酮最大降低65%,并在7.5天内恢复正常浓度(123.5微克/分升)。每日2次给予12毫克倍他米松(醋酸盐和磷酸盐)或每日4次给予6毫克倍他米松(酒精)治疗后,两种类固醇的抑制情况相似。12毫克剂量后倍他米松峰值水平较高,但两种治疗方案使胎儿在2.5天内暴露于升高的血清糖皮质激素活性的总时间相似,并在随后的4.5天内降低了血浆活性。出生时皮质醇浓度低的接受治疗的婴儿,在出生后因产时窒息或RDS,其皮质醇水平会升高数倍。倍他米松治疗不影响脐带血清催乳素水平,但生长激素浓度在各年龄段均降低。抑制作用在孕28至32周的婴儿中最大(降低53%),在较大婴儿中,治疗后2至4天内会随后升至对照水平以上。本研究表明,产前倍他米松治疗会导致胎儿生长激素的短暂抑制,可能还会抑制那些调节胎儿肾上腺确定区和胎儿区类固醇生成的垂体激素。然而,胎儿皮质醇的抑制并不干扰出生后垂体 - 肾上腺皮质对应激的反应。